Patient-friendly, non-technical summary of research papers

September 2026 Research Update

This report covers research on Niemann-Pick disease type C published in PubMed in September 2026. For other months, see all research updates.

Last update: October 10, 2026

At a glance

Gene change range

Reports from India showed many different NPC1 and NPC2 changes.

Missing DNA segments

Testing detected exon deletions that some gene tests may miss.

Liver and spleen signs

Some people had mainly liver and spleen findings at diagnosis.

Clearer diagnosis details

This month, the main new information was about diagnosis in India, including a wide range of NPC1/NPC2 gene changes and deletions that some tests can miss. Early reports often highlighted liver and spleen findings, with no clear change in treatment evidence.

Overview

This month, the clearest change in the literature was about diagnosis in India. The new report adds practical detail on what testing can pick up and what early symptoms may look like.

One key message was genetic variety. The report found many different changes in the NPC1 and NPC2 genes rather than one common cause. It also included gene changes that were new in this dataset. This supports the idea that genetic results can look very different from one family to another.

Another message was about what kinds of gene changes testing should look for. The approach used in this report detected exon-level deletions, which are a type of missing DNA segment. Some genetic tests can miss this kind of change if they mainly look for single-letter DNA differences.

On the symptom side, enlarged liver and spleen was the most common feature reported. Some people were described as having mostly body (visceral) symptoms without clear neurologic involvement at diagnosis. Cherry-red spots in the eye were also reported in several patients, adding to the range of eye findings described in this group.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Niemann-Pick disease type C update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month added a clearer picture of how Niemann-Pick disease type C (NPC) can look and be diagnosed in India, with results pointing to very high genetic variety rather than one or two common causes. A multicenter review found many different NPC1 and NPC2 gene changes across a relatively small group of patients, including previously unreported variants. In plain terms, the study shows that DNA testing needs to be able to detect many different types of changes, because NPC can be caused by a wide range of genetic variants in this population.

The study reported 32 variants in 28 patients, including 11 novel variants and two exon-level deletions, found mostly with a targeted sequencing panel for lysosomal storage disorders (an smMIP-based test, used in 25 of the 28 patients). This matters because deletions and other copy-number changes can be missed if testing only looks for simpler letter-by-letter DNA changes. The report also illustrates that multiple testing methods were used in practice (targeted testing, clinical exome sequencing, and Sanger sequencing), reflecting real-world pathways to reach a genetic diagnosis.

On the clinical side, enlarged liver and spleen was the most common feature, and the study noted that some people had mainly visceral disease without clear neurologic involvement at the time of diagnosis. The authors also described cherry-red spots in the eye in several patients, which broadens the set of eye findings reported in NPC in this setting. Put simply, the study reinforces that NPC may first show up as body (visceral) symptoms in some people, and that eye exams may occasionally add helpful clues.

For patients and caregivers, this mainly adds understanding about diagnosis rather than changing treatment decisions. It supports the idea that genetic confirmation can require tests that look for many different kinds of DNA changes, including deletions, and that the mix of variants may differ across regions and families. What remains uncertain is how often each newly reported variant truly causes disease, because the report noted limited family testing and limited functional follow-up for some variants. For now, the value is that this kind of work can help more families reach an explanation for symptoms and may improve future genetic counseling as variants are confirmed over time.

Limitations

The report covered a relatively small number of people from one country.
Family testing and lab follow-up were limited for some newly reported variants.
Clinical features were described at diagnosis, so later neurologic changes may not be captured.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.